The Influence of High Body Mass Index (BMI > 35 kg/m) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation.

Purpose: Apixaban, a direct oral anticoagulant is administered for stroke prevention in atrial fibrillation patients. Dosing adjustment is guided by renal function, age, and body weight. However, no data exist on its pharmacokinetics in patients with a body mass index (BMI) ≥ 35 kg/m.